{"id":2603,"date":"2020-05-14T00:00:00","date_gmt":"2020-05-13T22:00:00","guid":{"rendered":"https:\/\/www.ship2b.org\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation"},"modified":"2025-02-08T01:13:21","modified_gmt":"2025-02-08T00:13:21","slug":"admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation","status":"publish","type":"post","link":"https:\/\/www.ship2b.org\/ca\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/","title":{"rendered":"ADmit Therapeutics obtiene el respaldo de la Alzheimer&#8217;s Drug Discovery Foundation"},"content":{"rendered":"<p><a href=\"https:\/\/www.admit-therapeutics.com\/es\"><b>ADmit Therapeutics<\/b><\/a><span style=\"font-weight: 400\"> ha recibido una inversi\u00f3n de <\/span><b>497.652<\/b><b>\u00a0d\u00f3lares de la ADDF Diagnostics Accelerator<\/b><span style=\"font-weight: 400\"> para desarrollar su test de diagn\u00f3stico precoz de la enfermedad de Alzheimer en muestras de sangre. La convocatoria Diagnostics Accelerator es una iniciativa de investigaci\u00f3n que pretende acelerar el desarrollo de biomarcadores m\u00e1s espec\u00edficos y accesibles para diagnosticar la enfermedad de Alzheimer y otras demencias, promoviendo el avance en el desarrollo de f\u00e1rmacos personalizados. Para conocer m\u00e1s sobre la convocatoria visiten la p\u00e1gina web AlzDiscovery.org\/accelerator.<\/span><\/p>\n<p><span style=\"font-weight: 400\">La compa\u00f1\u00eda es una spin-off del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), situada en Barcelona, la cual ha recibido subvenciones nacionales y europeas, e inversiones privadas de Ship2B, GENESIS Biomed, BStartup10 y otros inversores desde su constituci\u00f3n a finales de 2017.<\/span><\/p>\n<h3 style=\"text-align: left\"><b>M\u00e1s sobre ADmit Therapeutics<\/b><\/h3>\n<p><span style=\"font-weight: 400\">En paralelo, ADmit Therapeutics, startup de impacto acelerada en el programa <\/span><a href=\"https:\/\/ship2b.org\/tech4health\/\"><span style=\"font-weight: 400\">S2B Tech4Health<\/span><\/a><span style=\"font-weight: 400\">, tiene abierta una <\/span><b>ronda en la plataforma <\/b><a href=\"https:\/\/capitalcell.es\/campaign\/admit\/\"><b>Capital Cell<\/b><\/a><span style=\"font-weight: 400\">, en la que ya ha alcanzado el <\/span><b>77% de los 400.000 euros <\/b><span style=\"font-weight: 400\">que le ofrecer\u00e1n el presupuesto necesario para obtener el objetivo 2020 para la validaci\u00f3n cl\u00ednica. El plan de desarrollo contempla el marcado CE en 2023 para poder comercializar un algoritmo predictivo y un software que proporcione el diagn\u00f3stico del paciente.\u00a0<\/span><\/p>\n<p><b>Equity4Good<\/b><span style=\"font-weight: 400\">, el fondo gestionado por Ship2B y que cuenta con el apoyo del Fondo Europeo de Inversi\u00f3n (FEI), realiza un<\/span><b> follow-on<\/b><span style=\"font-weight: 400\"> en esta operaci\u00f3n, reforzando as\u00ed su apuesta por el impacto que puede generar ADmit en la salud de las personas.\u00a0<\/span><\/p>\n<h3 style=\"text-align: left\"><b>Impactar en el diagn\u00f3stico precoz<\/b><\/h3>\n<p><span style=\"font-weight: 400\">Se calcula que m\u00e1s de <\/span><b>47 millones de personas en el mundo padecen Alzheimer<\/b><span style=\"font-weight: 400\"> y que la incidencia se ver\u00e1 incrementada considerablemente en los pr\u00f3ximos a\u00f1os debido al aumento de la esperanza de vida, llegando a los 130 millones de pacientes en 2050. Los tratamientos farmacol\u00f3gicos de los que se dispone en la actualidad son sintom\u00e1ticos y de limitada eficacia, sin que exista una terapia que cure o estabilice el proceso.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Existe un infra diagn\u00f3stico de los casos en Espa\u00f1a y en Europa (sobre todo en fase leve) y suele hacerse en fase moderada y con 12-24 meses de retraso tras el inicio de los s\u00edntomas. No existe ning\u00fan test de diagn\u00f3stico precoz implementado en la pr\u00e1ctica cl\u00ednica. El test de ADmit Therapeutics podr\u00eda ser el primer test in vitro efectivo para detectar el Alzheimer antes de que aparezca, lo que permitir\u00eda tanto diagnosticar la enfermedad como desarrollar f\u00e1rmacos para curarla, y alcanzar un valor mercado del orden de los cientos de millones de euros.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ADmit Therapeutics ha recibido una inversi\u00f3n de 497.652\u00a0d\u00f3lares de la ADDF Diagnostics Accelerator para desarrollar su test de diagn\u00f3stico precoz de la enfermedad de Alzheimer en muestras de sangre. La convocatoria Diagnostics Accelerator es una iniciativa de investigaci\u00f3n que pretende acelerar el desarrollo de biomarcadores m\u00e1s espec\u00edficos y accesibles para diagnosticar la enfermedad de Alzheimer &hellip; <a href=\"https:\/\/www.ship2b.org\/ca\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/\">Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[21],"tags":[187],"class_list":["post-2603","post","type-post","status-publish","format-standard","hentry","category-ship2b","tag-equity4good"],"acf":[],"yoast_head":"<title>ADmit Therapeutics obtiene el respaldo de la Alzheimer&#039;s Drug Discovery Foundation - Ship2B Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADmit Therapeutics obtiene el respaldo de la Alzheimer&#039;s Drug Discovery Foundation - Ship2B Foundation\" \/>\n<meta property=\"og:description\" content=\"ADmit Therapeutics ha recibido una inversi\u00f3n de 497.652\u00a0d\u00f3lares de la ADDF Diagnostics Accelerator para desarrollar su test de diagn\u00f3stico precoz de la enfermedad de Alzheimer en muestras de sangre. La convocatoria Diagnostics Accelerator es una iniciativa de investigaci\u00f3n que pretende acelerar el desarrollo de biomarcadores m\u00e1s espec\u00edficos y accesibles para diagnosticar la enfermedad de Alzheimer &hellip; Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/\" \/>\n<meta property=\"og:site_name\" content=\"Ship2B Foundation\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-13T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-08T00:13:21+00:00\" \/>\n<meta name=\"author\" content=\"monolitdigital\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"monolitdigital\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/\",\"url\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/\",\"name\":\"ADmit Therapeutics obtiene el respaldo de la Alzheimer's Drug Discovery Foundation - Ship2B Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.ship2b.org\/#website\"},\"datePublished\":\"2020-05-13T22:00:00+00:00\",\"dateModified\":\"2025-02-08T00:13:21+00:00\",\"author\":{\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/www.ship2b.org\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADmit Therapeutics obtiene el respaldo de la Alzheimer&#8217;s Drug Discovery Foundation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ship2b.org\/#website\",\"url\":\"https:\/\/www.ship2b.org\/\",\"name\":\"Ship2B Foundation\",\"description\":\"Adventurers for a better world\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ship2b.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb\",\"name\":\"monolitdigital\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g\",\"caption\":\"monolitdigital\"},\"url\":\"https:\/\/www.ship2b.org\/ca\/actualidad\/author\/monolitdigital\/\"}]}<\/script>","yoast_head_json":{"title":"ADmit Therapeutics obtiene el respaldo de la Alzheimer's Drug Discovery Foundation - Ship2B Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/","og_locale":"ca_ES","og_type":"article","og_title":"ADmit Therapeutics obtiene el respaldo de la Alzheimer's Drug Discovery Foundation - Ship2B Foundation","og_description":"ADmit Therapeutics ha recibido una inversi\u00f3n de 497.652\u00a0d\u00f3lares de la ADDF Diagnostics Accelerator para desarrollar su test de diagn\u00f3stico precoz de la enfermedad de Alzheimer en muestras de sangre. La convocatoria Diagnostics Accelerator es una iniciativa de investigaci\u00f3n que pretende acelerar el desarrollo de biomarcadores m\u00e1s espec\u00edficos y accesibles para diagnosticar la enfermedad de Alzheimer &hellip; Read more","og_url":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/","og_site_name":"Ship2B Foundation","article_published_time":"2020-05-13T22:00:00+00:00","article_modified_time":"2025-02-08T00:13:21+00:00","author":"monolitdigital","twitter_card":"summary_large_image","twitter_misc":{"Written by":"monolitdigital","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/","url":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/","name":"ADmit Therapeutics obtiene el respaldo de la Alzheimer's Drug Discovery Foundation - Ship2B Foundation","isPartOf":{"@id":"https:\/\/www.ship2b.org\/#website"},"datePublished":"2020-05-13T22:00:00+00:00","dateModified":"2025-02-08T00:13:21+00:00","author":{"@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb"},"breadcrumb":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-obtiene-el-respaldo-de-la-alzheimers-drug-discovery-foundation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.ship2b.org\/ca\/"},{"@type":"ListItem","position":2,"name":"ADmit Therapeutics obtiene el respaldo de la Alzheimer&#8217;s Drug Discovery Foundation"}]},{"@type":"WebSite","@id":"https:\/\/www.ship2b.org\/#website","url":"https:\/\/www.ship2b.org\/","name":"Ship2B Foundation","description":"Adventurers for a better world","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ship2b.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb","name":"monolitdigital","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g","caption":"monolitdigital"},"url":"https:\/\/www.ship2b.org\/ca\/actualidad\/author\/monolitdigital\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/posts\/2603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/comments?post=2603"}],"version-history":[{"count":2,"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/posts\/2603\/revisions"}],"predecessor-version":[{"id":10439,"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/posts\/2603\/revisions\/10439"}],"wp:attachment":[{"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/media?parent=2603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/categories?post=2603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ship2b.org\/ca\/wp-json\/wp\/v2\/tags?post=2603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}